“…9 Lamivudine has been shown to produce three crystalline forms, form I, which is a 0.2 hydrate that exhibits needle geometry, and two anhydrous forms, form II, and III which typically adopt bipyramidal 10 and needle morphologies, respectively. 11 Existing patents state that form I and form II are preferred in solid oral dosing. 12 Therefore, the objective of the crystallisation is the purification and management of physical attributes to ease downstream processing.…”